GMTX vs. OGN, IONS, BBIO, CYTK, MDGL, APLS, ALPN, NUVL, ALKS, and PRGO
Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), Cytokinetics (CYTK), Madrigal Pharmaceuticals (MDGL), Apellis Pharmaceuticals (APLS), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Organon & Co. (NYSE:OGN) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, community ranking, earnings, risk and media sentiment.
Organon & Co. currently has a consensus target price of $22.60, suggesting a potential upside of 5.95%. Given Gemini Therapeutics' higher probable upside, analysts clearly believe Organon & Co. is more favorable than Gemini Therapeutics.
In the previous week, Organon & Co. had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 4 mentions for Organon & Co. and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 1.39 beat Organon & Co.'s score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media.
Gemini Therapeutics received 3 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 63.33% of users gave Gemini Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
Organon & Co. has a net margin of 16.50% compared to Organon & Co.'s net margin of 0.00%. Organon & Co.'s return on equity of -38.78% beat Gemini Therapeutics' return on equity.
Organon & Co. has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
Organon & Co. has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500.
77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Organon & Co. beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Gemini Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemini Therapeutics Competitors List
Related Companies and Tools
